Better Therapeutics IncOOTC BTTX Stock Report

Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. The company is headquartered in San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive-behavioral therapy to address the root causes of cardiometabolic diseases. The firm's Nutritional Cognitive Behavioral Therapy (Nutritional CBT) is a novel form of behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. The company targets the cognitive structures, behavioral routines, emotional patterns, and coping skills that underlie culturally specific eating behaviors. Its clinical development pipeline includes BT-001, BT-002, BT-003, and BT-004. The BT-001 is an investigational PDT platform that is designed to use digitally delivered Nutritional CBT to treat type 2 diabetes. The firm's platform consists of three integrated components, behavioral therapy, treatment plans, and personalization. Its behavioral therapy consists of lessons, skill-building modules, and a mechanism for goal setting.